Evidence map›Paper›PMID 35998675›Full record

ArticleBlood2022

Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies.

Adam J Kanack, Curtis G Jones, Bandana Singh, Rachel R Leger, Noah P Splinter, Nahla M Heikal, Rajiv K Pruthi, Dong Chen, Gemlyn George, Mouhamed Y Abou-Ismail and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT.medRxiv : the preprint server for health sciences · 2025
    Article
  3. In vitro Generated Megakaryocytes for the Detection of Human Platelet Antigen-Specific Alloantibodies.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Vaccine-induced immune thrombotic thrombocytopenia.Best practice & research. Clinical haematology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Adam J KanackDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Curtis G JonesRetham Technologies, Wauwatosa, WI.
Bandana SinghDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Rachel R LegerSpecial Coagulation Laboratory, Mayo Clinic, Rochester, MN.
Noah P SplinterDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Nahla M HeikalDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Rajiv K PruthiDepartment of Medicine, Mayo Clinic, Rochester, MN.
Dong ChenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Gemlyn GeorgeDepartment of Medicine, University of Colorado, Aurora, CO.
Mouhamed Y Abou-IsmailDepartment of Internal Medicine, University of Utah, Salt Lake City, UT.ORCID 0000-0002-6682-4366
Geoffrey D WoolDepartment of Pathology, University of Chicago, Chicago, IL.ORCID 0000-0002-3335-2905
Krishna GundaboluDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-4206-7468
Anand PadmanabhanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2519-4377
Mayo Clinic in Arizona · USMayo Clinic in Florida · USUniversity of Chicago · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Nebraska Medical Center · USUniversity of Utah · US

Funding

An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopeniaR44HL147734 · NHLBI · RETHAM TECHNOLOGIES, INC. · PI Curtis Jones · 2022 to 2026
$4.6M
New Approaches to Pathogenesis and Diagnosis of Heparin-Induced Thrombocytopenia (HIT)K08HL133479 · NHLBI · VERSITI WISCONSIN, INC. · PI PADMANABHAN, ANAND · 2017 to 2021
$836k
An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced ThrombocytopeniaR43HL147734 · NHLBI · RETHAM TECHNOLOGIES, INC. · PI JONES, CURTIS · 2019 to 2019
$225k
NHLBI NIH HHS K08 HL133479NHLBI NIH HHS R43 HL147734NHLBI NIH HHS R44 HL147734
6 · The paper itself

Abstract

Heparin-induced thrombocytopenia (HIT) is suspected much more often than it is confirmed. Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunosorbent assays (ELISAs) are sensitive but nonspecific. In contrast, accurate functional tests such as the serotonin release assay, heparin-induced platelet activation assay, and PF4-dependent P-selectin expression assay require fresh platelets and have complex assay end points, limiting their availability to specialized reference laboratories. To enable broad deployment of functional testing, we sought to extend platelet viability significantly by optimizing storage conditions and developed a simple functional assay end point by measuring the release of a platelet α-granule protein, thrombospondin-1 (TSP1), in an ELISA format. Platelet cryopreservation conditions were optimized by freezing platelets at controlled cooling rates that preserve activatability. Several-month-old cryopreserved platelets were treated with PF4 or heparin and were evaluated for their ability to be activated by HIT and vaccine-induced immune thrombotic thrombocytopenia (VITT) antibodies in the TSP1 release assay (TRA). HIT and spontaneous HIT patient samples induced significantly higher TSP1 release using both PF4-treated (PF4-TRA) and heparin-treated cryopreserved platelets relative to samples from patients suspected of HIT who lacked platelet-activating antibodies. This latter group included several patients that tested strongly positive in PF4-polyanion ELISA but were not platelet-activating. Four VITT patient samples tested in the TRA activated PF4-treated, but not heparin-treated, cryopreserved platelets, consistent with recent data suggesting the requirement for PF4-treated platelets for VITT antibody detection. These findings have the potential to transform the testing paradigm in HIT and VITT, making decentralized, technically simple functional testing available for rapid and accurate in-hospital diagnosis.

Indexed as

AntibodiesPurpura, Thrombocytopenic, IdiopathicThrombocytopeniaAnticoagulantsBlood PlateletsCryopreservationEnzyme-Linked Immunosorbent AssayHeparinHumansPlatelet Factor 4VaccinesAntibodiesAnticoagulantsHeparinPlatelet Factor 4Vaccines

Identifiers

PMID35998675
PMCPMC9837435
OpenAlexW4293261781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.